StockMarketWire.com - Tiziana Life Sciences announces new data from animal studies demonstrating the potential of its novel oral therapy with foralumab (NI-0401) for NASH, diabetes and other life-threatening inflammatory diseases.
Tiziana's foralumab is the only fully human engineered anti-CD3 monoclonal antibody (mAb) in clinical development to date.
HIGHLIGHTS:
- Oral efficacy in humanized mouse models with foralumab (NI-0401), is a major milestone and a potential breakthrough for treatment of NASH and autoimmune disease
- Unique oral technology that stimulates the natural gut immune system and potentially provides a therapeutic effect in inflammatory and autoimmune diseases with virtually no toxicity
- Positive therapeutic effects of foralumab were consistently demonstrated in animal studies conducted by Prof. Kevan Herold (Yale University) and Prof. Howard Weiner (Harvard University).
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.